#FMXIN002
LightNews LightNews
newsen.bsky.social
Nasus Pharma Reveals Promising Phase 2 Study Results for FMXIN002, a Novel Intranasal Epinephrine Powder#Israel#Tel_Aviv#Nasus_Pharma#FMXIN002#Anaphylaxis
Nasus Pharma Reveals Promising Phase 2 Study Results for FMXIN002, a Novel Intranasal Epinephrine Powder
Nasus Pharma announces positive results from its Phase 2 study of FMXIN002, a needle-free intranasal epinephrine powder, aimed at treating severe allergies.
third-news.com
June 3, 2025 at 12:24 PM
newsen.bsky.social
Nasus Pharma to Showcase Promising Clinical Findings on FMXIN002 at AAAAI 2025#Israel#Tel_Aviv#Allergy_Treatment#Nasus_Pharma#FMXIN002
Nasus Pharma to Showcase Promising Clinical Findings on FMXIN002 at AAAAI 2025
At the upcoming 2025 AAAAI Annual Meeting, Nasus Pharma will reveal significant insights from clinical trials of FMXIN002, a groundbreaking intranasal epinephrine product.
third-news.com
February 27, 2025 at 1:40 PM
l2plabs.bsky.social
Nasus Pharma Announces the Publication of Positive Clinical Results from its Phase 2 Study of FMXIN002 (NS002) Intranasal Epinephrine Powder
TEL AVIV, Israel, June 3, 2025 /PRNewswire/ -- Nasus Pharma Ltd. ("Nasus Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on developing needle-free, powder-based intranasal ("PBI") products addressing acute, community based, medical emergencies, today...
dlvr.it
June 3, 2025 at 12:22 PM
l2plabs.bsky.social
Nasus Pharma To Present Positive Clinical Results From Recent studies of FMXIN002 (NS002) Intranasal Epinephrine at the 2025 AAAAI Annual Meeting
TEL AVIV, Israel, Feb. 27, 2025 /PRNewswire/ -- Nasus Pharma Ltd. ("Nasus Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on developing needle-free, powder-based intranasal ("PBI") products addressing acute, community based,…
dlvr.it
February 27, 2025 at 1:02 PM